
Author Index

A

Abbott, R.D., 504
Abraham, A., 679
Adams, M.A., 1296
Akanuma, H., 723
Akanuma, Y., 723
Akaoka, I., 723
Akashi, M., 1573
Akazawa, M., 1573
Akazawa, S., 1573
Akiyama, N., 231
Alderson, D., 386
Alejandro, R., 698
Alexander, W.J., 629
Allison, J., 815
Almira, E.C., 152
Almus, F.E., 212
Alvarez-Buylla, R., 410
Amato, M.P., 310
Andersen, H.U., 1211
Andersen, L.C., 1381
Andersson, A., 510, 1326
Andersson, L.C., 667
Andreani, D., 1478
Ariño, J., 793
Arner, P., 524
Aronstam, R.S., 1611
Arquilla, E.R., 343, 868
Artavia-Loria, E., 477
Attvall, S., 1357
Avogaro, A., 75, 1048
Axelrod, L., 539, 1123, 1585
Azar, S., 839
Azhar, S., 1155

B

Baba, S., 1042
Baceij, A., 441, 1492
Bach, J.-F., 249
Bae, Y.-S., 316
Baekkeskov, S., 1133
Bagdade, J.D., 1226
Bagger, J.P., 1175
Bailbé, D., 610
Bak, J.F., 1343
Baldini, P., 825
Banerji, M.A., 784
Banskota, N.K., 123
Barbosa, J., 516
Bardet, S., 634
Barlascini, C.O., 273
Bartlett, S.T., 465
Basalyga, B.S., 1036
Basdevant, A., 477

Bass, E.B., 1456
Bassett, P.D., 244
Basty, E.J. III, 1097
Baxter, A.G., 1296
Baxter, J., 1231
Bayo, F., 237
Beard, J.C., 562
Beck, F., 773
Becker, D.J., 1456
Beggs, J.L., 1245
Bell, G.I., 17, 947, 1072
Bell, P.R.F., 244
Beltz, W.F., 1549
Bennett, P.H., 435, 1423
Benzi, L., 1579
Berman, R.N., 562, 1512
Bergman, T., 819
Bernardi, L., 589
Berti-Mattera, L.N., 373
Bertrand, G., 1291
Bessman, A.N., 659
Bestetti, G.E., 471, 1301, 1351
Bethke, K.P., 448
Bhathena, S.J., 691
Bier, D.M., 1048
Bierman, E.L., 117
Biggers, D.W., 7
Bilous, R.W., 1142
Binder, C., 1193, 1271
Björk, E., 1326
Black, S.C., 969
Blackard, W.G., 273, 285
Blaisdell, P., 1528
Blaner, W.S., 1544
Blondel, O., 610
Bloom, A.D., 698
Bloom, S.R., 321, 1114, 1200
Boemi, M., 932
Boeri, D., 212
Bogardus, C., 1423
Boitard, C., 249
Bolli, G.B., 1193
Bompiani, G., 718
Bonifacio, E., 172, 1275
Bonner, R.F., 819
Bonner-Weir, S., 49
Bonnevie-Nielsen, V., 1636
Borgos, J., 819
Borkman, M., 1314
Bortolami, M.C., 1012
Bosch, F., 793
Bosch, J.P., 679
Bose, P., 1036
Bostrom, M., 906
Bottazzo, G.F., 1275, 1396
Bouchard, C., 304

Bougnères, P.-F., 477
Boujon, C.E., 471, 1351
Boyd, A.E. III, 188, 874
Bracy, D., 799
Brady, D., 991
Brady, L.J., 65
Brady, P.S., 65
Brand, F.N., 504
Brechtel, G., 1549
Breitmeyer, J., 1462
Brelje, T.C., 808
Bretzel, R.G., 1402
Brillon, D.J., 397
Brink, S.J., 938
Brinn, J.E., 1337
Bristow, J.D., 1048
Brooks, D.P., 54
Brooks, R.A., 1200
Brown, A.T., 428
Brown, D.M., 130, 839
Brown, F.M., 938
Brunetti, A., 1579
Bryer-Ash, M., 108
Buchan, A.M.J., 1390
Buchanan, C., 1217
Buchanan, T.A., 1063
Burrin, J.M., 1114
Burstein, D., 24
Butler, L., 887
Byers, M.G., 1072

C

Cagliero, E., 212
Cahill, G., Jr., 404
Campbell, I.L., 815
Cantell, K., 641
Capani, F., 550
Capogreco, C., 257
Cardella, F., 718
Cardoso, H.M., 321
Caro, J.F., 1217
Carrier, G.O., 1611
Carsten, R.E., 730
Carswell, N., 679
Caruso, C., 310
Caruso, M., 1595
Casamitjana, R., 1396
Caspers-Velu, L.E., 1469
Castaño, L., 477
Cataland, S., 704
Chakrabarti, S., 1067, 1181
Chamberlain, J., 244
Chan, E.K., 1329
Chang, H., 1155

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139
February, 141-271
March, 273-404

April, 405-538
May, 539-669
June, 571-814

July, 815-945
August, 947-1075
September, 1077-1202

October, 1203-1331
November, 1333-1500
December, 1501-1651

Author Index

A

Abbott, R.D., 504
Abraham, A., 679
Adams, M.A., 1296
Akanuma, H., 723
Akanuma, Y., 723
Akaoaka, I., 723
Akashi, M., 1573
Akazawa, M., 1573
Akazawa, S., 1573
Akiyama, N., 231
Alderson, D., 386
Alejandro, R., 698
Alexander, W.J., 629
Allison, J., 815
Almira, E.C., 152
Almus, F.E., 212
Alvarez-Buylla, R., 410
Amato, M.P., 310
Andersen, H.U., 1211
Andersen, L.C., 1381
Andersson, A., 510, 1326
Andersson, L.C., 667
Andreani, D., 1478
Ariño, J., 793
Arner, P., 524
Aronstam, R.S., 1611
Arquilla, E.R., 343, 868
Artavia-Loria, E., 477
Attvall, S., 1357
Avogaro, A., 75, 1048
Axelrod, L., 539, 1123, 1585
Azar, S., 839
Azhar, S., 1155

B

Baba, S., 1042
Baceij, A., 441, 1492
Bach, J.-F., 249
Bae, Y.-S., 316
Baekkeskov, S., 1133
Bagdade, J.D., 1226
Bagger, J.P., 1175
Bailbé, D., 610
Bak, J.F., 1343
Baldini, P., 825
Banerji, M.A., 784
Banskota, N.K., 123
Barbosa, J., 516
Bardet, S., 634
Barlascini, C.O., 273
Bartlett, S.T., 465
Basalyga, B.S., 1036
Basdevant, A., 477

Bass, E.B., 1456
Bassett, P.D., 244
Basty, E.J. III, 1097
Baxter, A.G., 1296
Baxter, J., 1231
Bayo, F., 237
Beard, J.C., 562
Beck, F., 773
Becker, D.J., 1456
Beggs, J.L., 1245
Bell, G.I., 17, 947, 1072
Bell, P.R.F., 244
Beltz, W.F., 1549
Bennett, P.H., 435, 1423
Benzi, L., 1579
Berman, R.N., 562, 1512
Bergman, T., 819
Bernardi, L., 589
Berti-Mattera, L.N., 373
Bertrand, G., 1291
Bessman, A.N., 659
Bestetti, G.E., 471, 1301, 1351
Bethke, K.P., 448
Bhathena, S.J., 691
Bier, D.M., 1048
Bierman, E.L., 117
Biggers, D.W., 7
Bilous, R.W., 1142
Binder, C., 1193, 1271
Björk, E., 1326
Black, S.C., 969
Blackard, W.G., 273, 285
Blaisdell, P., 1528
Blaner, W.S., 1544
Blondel, O., 610
Bloom, A.D., 698
Bloom, S.R., 321, 1114, 1200
Boemi, M., 932
Boeri, D., 212
Bogardus, C., 1423
Boitard, C., 249
Bolli, G.B., 1193
Bompiani, G., 718
Bonifacio, E., 172, 1275
Bonner, R.F., 819
Bonner-Weir, S., 49
Bonnevie-Nielsen, V., 1636
Borgos, J., 819
Borkman, M., 1314
Bortolami, M.C., 1012
Bosch, F., 793
Bosch, J.P., 679
Bose, P., 1036
Bostrom, M., 906
Bottazzo, G.F., 1275, 1396
Bouchard, C., 304

Bougnères, P.-F., 477
Boujon, C.E., 471, 1351
Boyd, A.E. III, 188, 874
Bracy, D., 799
Brady, D., 991
Brady, L.J., 65
Brady, P.S., 65
Brand, F.N., 504
Brechtel, G., 1549
Breitmeyer, J., 1462
Brelje, T.C., 808
Bretzel, R.G., 1402
Brillon, D.J., 397
Brink, S.J., 938
Brinn, J.E., 1337
Bristow, J.D., 1048
Brooks, D.P., 54
Brooks, R.A., 1200
Brown, A.T., 428
Brown, D.M., 130, 839
Brown, F.M., 938
Brunetti, A., 1579
Bryer-Ash, M., 108
Buchan, A.M.J., 1390
Buchanan, C., 1217
Buchanan, T.A., 1063
Burrin, J.M., 1114
Burstein, D., 24
Butler, L., 887
Byers, M.G., 1072

C

Cagliero, E., 212
Cahill, G., Jr., 404
Campbell, I.L., 815
Cantell, K., 641
Capani, F., 550
Capogreco, C., 257
Cardella, F., 718
Cardoso, H.M., 321
Caro, J.F., 1217
Carrier, G.O., 1611
Carsten, R.E., 730
Carswell, N., 679
Caruso, C., 310
Caruso, M., 1595
Casamitjana, R., 1396
Caspers-Velu, L.E., 1469
Castaño, L., 477
Cataland, S., 704
Chakrabarti, S., 1067, 1181
Chamberlain, J., 244
Chan, E.K., 1329
Chang, H., 1155

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139
February, 141-271
March, 273-404

April, 405-538
May, 539-669
June, 571-814

July, 815-945
August, 947-1075
September, 1077-1202

October, 1203-1331
November, 1333-1500
December, 1501-1651

AUTHOR INDEX 1989

Chang, K., 1258
Chao, T., 1643
Charbonnel, B., 634
Charles, M.A., 1329
Charlton, B., 441, 1492
Chatenoud, L., 249
Chavers, B., 1077
Cherrington, A.D., 7, 484, 799, 1193
Chertow, B.S., 1544
Chesterman, C.N., 1314
Chiavetta, A., 1579
Chiba, T., 1005
Chirra, A.R., 194
Chisholm, D.J., 499, 1314
Christie, M., 1133
Ciaraldi, T.P., 951, 991
Clark, C.M., Jr., 1506
Clark, O.H., 219
Clore, J.N., 273, 285
Cobelli, C., 1048
Cochrane, C., 1433
Cogswell, B.E., 959
Cohen, K., 881
Cole, T.G., 604
Colle, E., 911
Collins, V.R., 1602
Colman, P.G., 779, 1478
Consoli, A., 550, 744
Cook, D.L., 416
Cook, J.J., 779
Cooper, N.B., 7
Cordle, M.B., 1544
Cornblath, D.R., 1365
Corvol, M., 686
Court, J.M., 779
Cox, N.J., 17, 653, 947
Craig, E.L., 704
Crofton, J.T., 54
Cryer, P.E., 405, 1193
Curry, D.L., 465
Cutler, P., 1207
Czernichow, P., 686

D

D'Alessio, D.A., 1534
Da Campo, G.L., 75
Dahlqvist, G., 1271
Daley, J., 1462
The Damad Study Group, 491
Damjanov, I., 1056
Daniels, B.S., 981
Daugherty, A., 1484
Day, S.-F., 373
Dean, B., 779
Dean, B.M., 1275
Deery, D., 49
DeGruccio, A., 194
De Haan, M., 1623
De Leeuw, I., 1412
Dershimer, R.C., 1097
Després, J.-P., 304
Diaz, J.-L., 172

Di Giambardino, L., 1012
DiGirolamo, M., 237
Dimarchi, R., 1217
Di Mario, U., 1478
Ding, H.L., 562
Dobrjansky, A., 1165
Donadon, V., 75
Donà, M., 1012
Doria, A., 75
Dorman, J.S., 1456
Dotta, F., 1478
Dowse, G.K., 1602
Drash, A.L., 534, 1456
Drexhage, H.A., 1623
Drobný, E., 819
Duet, J., 1539
Dunai, A., 1165
Dunger, D.B., 1275
Dunlap, J.A., 996
Dunlop, M.E., 1187

E

Eades, D.M., 1258
Easom, R.A., 1251
Eckel, R.H., 710
Eddy, R.L., 1072
Edwards, S., 868
Eichberg, J., 373
Eide, C.R., 146
Eifler, C.W., 975
Eisenbarth, G.S., 358, 1320, 1462, 1478
Elbein, S.C., 737
Ellis, T.R., 1371
Engelmann, G.J., 1412
Engerman, R.L., 1203
Engelhardt, P., 524
Enriquez, A.J., 1148
Ensinck, J.W., 1534
Epstein, P.A., 653
Ercilla, G., 1396
Eriksson, R.S.M., 764
Eriksson, U.J., 764
Esposito-Del Puente, A., 1423
Eun, H.-M., 316

F

Fabris, M., 1012
Fabris, N., 932
Fagin, J.A., 428
Falk, L.C., 422
Fan, Y.-S., 1072
Faustman, D., 1462
Federlin, K., 1402
Feinglos, M.N., 1433
Feingold, K.R., 141, 219
Feldman, E.C., 698
Ferland, M., 304
Feutren, G., 249
Fève, B., 634
Fey, S., 1133

Finardi, G., 589
Finch, C.F., 1602
Fink, R.I., 1549
Fioretto, P., 75
Fiori, M.G., 1012
Fisher, E., 257
Fletcher, D.J., 1337
Flier, J.S., 1496
Ford, C., 618
Forrest, L.E., 1329
Fowelin, J., 1357
Franklin, G., 58
Fratino, P., 589
Frazier, M.L., 975
Freeman, R., 938
Freidenberg, G.R., 397
Frifelt, J.J., 1636
Fritsch, R., 1617
Frizzell, R.T., 7
Froguel, P., 164
Fröhlich, M., 1082
Fujimoto, W.Y., 625, 1534
Fuks, A., 911
Fukudo, S., 1433
Fumelli, P., 932
Furley, S.M., 1314
Futterweit, W., 1165

G

Gabbay, K.H., 942
Gaines, J.A., 1245
Gale, E.A.M., 1193, 1275
Galluzzo, A., 310
Garg, A., 364
Garrett, J.R., 1381
Gatta, C., 1417
Gee, W.M., 422
Gelfand, R.A., 1117
Gerald, M.C., 278
Gerich, J.E., 550, 744, 1193
Ghahary, A., 1067
Ghatei, M.A., 1200
Giardina, E., 718
Gilbey, S.G., 1114
Gill, J.S., 321
Gilligan, A., 1056
Gillis, K.D., 422
Gillison, S.L., 465
Giorda, R., 1617
Giordano, C., 310
Girman, D.J., 194
Giron, D.J., 1103
Gispen, W.H., 225
Goertz, G., 906
Goetz, F.C., 516
Goldfine, I.D., 182
Goldstein, R.E., 484
Goldstein, S., 758
Gómez-Foix, A.M., 793
Gomis, R., 1396
Gong, Y., 1067
Goodner, C.J., 925

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139
February, 141-271
March, 273-404

April, 405-538
May, 539-669
June, 671-814

July, 815-945
August, 947-1075
September, 1077-1202

October, 1203-1331
November, 1333-1500
December, 1501-1651

AUTHOR INDEX 1989

Gooszen, H.G., 1082
Gotoh, M., 861
Grave, G., 534
Greene, D.A., 1456
Greenwood, M.R.C., 159
Greer, M.K., 267
Greiner, D.L., 24
Grodsky, G.M., 673
Gross, R., 1291
Grundy, S.M., 364
Grunfeld, C., 987
Guarner, V., 410
Guberski, D.L., 887
Guerrero, J.L., 1585
Guicherit, O.R., 1082
Guidolin, D., 1012
Guinovart, J.J., 793
Gullo, D., 1417
Gumbiner, B., 1549
Gunn, S., 942
Guttmann, R.D., 911

H

Habener, J.F., 338
Haffner, S.M., 975
Halkin, H., 1630
Hallberg, A., 1326
Halliday, D., 618
Hamlin, R.L., 854
Hamman, R.F., 1231
Hammes, H.P., 1402
Handler, E.S., 24
Hansen, B.C., 1365
Harris, M.I., 1630
Harrison, L.C., 779, 815
Hartling, S.G., 1271
Hashimoto, H., 231
Hashimoto, M., 1573
Hashimoto, Y., 1109
Hatanaka, I., 832
Hattori, M., 358
Hayes, G.R., 205
Haymond, M.W., 97, 847, 1238
Hazuda, H.P., 975
Heffernan, S., 257
Hegre, O.D., 146, 1148
Heiling, V., 1595
Held, M., 1577
Helqvist, S., 1211
Helve, E., 580
Hendrick, G.K., 338
Henningsen, P., 1175
Henquin, J.-C., 198
Henriksson, J., 906
Henry, R.R., 397
Henry, S., 477
Herbst, J.J., 1539
Herman, C.N., 1365
Hermans, M.P., 198
Hildebrandt, W., 1231
Hill, R.S., 874
Hillaire-Buys, D., 1291

Hillman, M.A., 1365
Hindson, D.A., 1031
Hirata, Y., 663, 1090
Hoffman, B.B., 1155
Holowachuk, E.W., 267
Holthöfer, H., 667
Horber, F., 1238
Horton, M.B., 435
Hostetter, T.H., 981
Houssaint, E., 634
Hu, K.-Q., 1643
Huang, P., 17
Hudson, I., 779
Hughes, J.H., 1251
Huitian, Z., 832
Hullett, D.A., 448
Hunter, E.S. III, 70

I

Iaffaldano, R., 1585
Ideura, T., 1109
Ikeuchi, M., 416
Incerpi, S., 825
Ishiguro, T., 91
Ishii, D.N., 730
Ito, A., 1005
Ito, T., 231
Itoh, H., 902
Iwakiri, R., 558
Iwamoto, Y., 262

J

Jackson, R.A., 1320
Jacobs, D.B., 205
Jain, S.K., 1539
James, R.F.L., 244
Janeway, C.A., Jr., 1647
Janke, H.U., 460
Jansen, J.B.M.J., 1082
Jansson, L., 510
Jaspan, J.B., 7
Jenkins, A.B., 499
Jennings, A.M., 1275
Jensen, M.D., 1595
Jeucken, P.H.M., 1623
Jewett, L., 1056
Jiao, S., 604
Johnson, P.C., 1245

K

Kabel, P.J., 1623
Kador, P.F., 1469
Kadrofske, M.M., 1097
Kahn, C.R., 31
Kahn, S.E., 562, 1333
Kajinuma, H., 1567
Kämpe, O., 1326

Kannel, W.B., 504
Kanse, S.M., 1200
Kaptur, P.E., 1103
Karam, J.H., 17
Karsson, F.A., 1326
Karzon, S.-L., 580
Kassm, H.M., 1036
Kastern, W., 887
Katz, M.A., 1245
Katz, S., 969
Kava, R.A., 159
Kayano, T., 1072
Keahey, H.H., 188
Keen, C.L., 1282
Keller, U., 454
Kenyon, N.S., 698
Kern, P.A., 710
Ketchum, R.J., 146, 1148
Khazanie, P.G., 1217
Kikkawa, U., 1005
Kilo, C., 1258, 1484
Kimmel, P.L., 679
King, G.L., 123, 1643
Klandorf, H., 194
Klein, D.J., 130
Kloer, H.U., 1402
Kneteman, N.M., 386
Knowler, W.C., 435, 1423
Knowles, B.B., 1056
Koerker, D.J., 925
Kohner, E.M., 1200
Koivisto, V.A., 641
Komatsu, R., 902
Kono, N., 902
Kontiainen, S., 667
Korsgren, O., 510
Koshikawa, S., 1109
Kover, K., 917
Kraegen, E.W., 499, 1314
Kriaucunas, K.M., 31
Krolewski, A.S., 460
Kruse, V., 172
Kudlacz, E.M., 278
Kulin, C.M., 1433
Kuller, L.H., 1456
Kunze, D.L., 188
Kuzuya, T., 262

L

Lacy, D.B., 484, 799
Lacy, P.E., 379, 386
LaFace, D.M., 887
Lager, I., 1357
Lake, S.P., 244
Lambert-Gardini, S., 825
Lamers, C.B.H.W., 1082
Land, M.P., 1484
Lander, T., 1557
Landry, A.S., 448
Lane, J., 1123
Larkins, R.G., 1187
Larsen, M.L., 1636

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139
February, 141-271
March, 273-404

April, 405-538
May, 539-669
June, 671-814

July, 815-945
August, 947-1075
September, 1077-1202

October, 1203-1331
November, 1333-1500
December, 1501-1651

AUTHOR INDEX 1989

Larsen, P.M., 1133
Larson, K.B., 1484
Lash, J.M., 854
Leahy, J.L., 49
Lebovitz, H.E., 784
Lee, T.-S., 1643
Lee, Y.C., 321
Leeney, E.M., 996
Leggett, N., 1217
Lehtinen, J.M., 1307
Leiter, E.H., 1446
Lemarchand-Béraud, T., 1351
Lenti, L., 1478
Leonard, D.K., 448
Lernmark, Å., 1636
LeRoith, D., 428
Levine, R., 1
Like, A.A., 887
Likhite, V., 1329
Lillioja, S., 1423
Lindgren, F., 1271
Linn, T., 1402
Linnane, A.W., 1602
Litzlbauer, D., 1402
Locker, J., 39
Lockwood, D.H., 205
Logsdon, C.D., 182
Lombardi, D., 1478
London, N.J.M., 244
Lönnqvist, F., 524
Lorenzi, M., 212
Loubatières-Mariani, M.-M., 1291
Lowery, J., 373
Lukasik, V.A., 159
Luly, P., 825
Luo, J., 1067
Lupien, P.J., 304

M
MacLaren, N., 534
Maddux, B.A., 182
Maiello, M., 212
Malarkey, W.B., 704
Mandel, T.E., 441, 1296, 1492
Mandrup-Poulsen, T., 1211
Manjoo, Q., 1456
Marini, P., 1012
Marsh, H.M., 291
Marshall, J.A., 1231
Marti, G., 589
Martin, L., 1217
Martin, P., 1161
Maser, R.E., 1456
Massol, J., 1161
Matschinsky, F.M., 1056
Matsuda, A., 262
Matsuyama, T., 902
Mauer, S.M., 516, 839, 1077, 1142
Mayer, E.J., 1231
McCulloch, D.K., 925
McCuskey, P., 1245
McDaniel, M.L., 1251

McDonald, A.R., 182
McDonald, J.M., 84
McDougall, B.R., 343, 868
McFarland, K.C., 987
McHugh, L.E., 516
McLennan, S., 257
McMahon, M.M., 97, 291
McNally, J.M., 1275
McNeill, J.H., 969, 1390
McVie, R., 1539
Mehnert, H., 1557
Meli, F., 718
Meloche, R.M., 146
Mendola, J., 379
Michaelis, O.E. IV, 679, 691
Michelsen, B., 1636
Miettinen, A., 667
Miettinen, M., 667
Miles, J.M., 847, 1595
Miller, J.F.A.P., 815
Miley, J.R., 597
Minkowski, O., 1
Minoda, S., 723
Misbin, R.I., 152
Misler, S., 422
Mitchell, B.D., 975
Miyashita, H., 723
Miyata, H., 1567
Moberly, J.B., 604
Moccagiani, E., 932
Modan, M., 1630
Modica, M.A., 310
Mojsov, S., 338
Molina, J.M., 991
Moller, D.E., 1496
Mølvig, J., 1211
Monden, M., 861
Mongillo, S., 75
Moore, M.R., 1544
Moore, W.V., 146, 917
Moorjani, S., 304
Moo-Young, G.A., 1231
Mordes, J.P., 24
Mori, T., 861
Moser, A.H., 219
Mosqueda, L., 868
Mott, D.M., 1423
Moulton, A.W., 350
Muglia, L., 39
Muller-Wieland, D., 31
Murakami, H., 1090
Murphy, L.J., 1067
Murphy, V.A., 1469
Murray, J.C., 1072
Myers, S.R., 7

N
Nadeau, A., 304
Nagafuchi, S., 558
Nagataki, S., 1573
Nagy, M.V., 1329
Nair, K.S., 618

Najarian, J.S., 516
Nakamura, N., 24
Nakamura, Y., 1072
Nakanishi, T., 1573
Namba, M., 902
Nathan, D.M., 350
Nayak, R.C., 1478
Neal, D., 7
Nelson, D.L., 249
Nelson, D.M., 1439
Nelson, L., 58
Nelson, R.G., 435
Nerl, C., 1557
Nerup, J., 1211
Nestler, J.E., 273, 285
Newby, F.D., 237
Nie, Z., 906
Nielsen, T.T., 1175
Nielsen, V.K., 1456
Nielsen, C.P., 1031
Nikkilä, E.A., 580
Noke, M., 1402
Nosadini, R., 75
Nurjhan, N., 550, 744
Nutting, D.F., 54
Nyomba, B.L., 1423

O
O'Donnell, G., 819
O'Dorisio, T.M., 704
Oegema, T.R., Jr., 130
Ogawa, K., 231
O'Halloran, D.J., 1114
Ohki, A., 1042
Okabayashi, Y., 182, 1042
Okamura, J., 861
Okpere, B.E., 321
Okumura, K., 231
Olefsky, J.M., 397, 991
Olsen, P., 123
Omori, Y., 1090
Ono, S.J., 911
Oppenheimer, M.J., 117
Orchard, T.J., 1456
Osei, K., 704
Oshida, Y., 91
Østerby, R., 1077
Otsuki, M., 1042
Owerbach, D., 942

P
Pabst, S.J., 1337
Pacy, P.J., 618
Page, J., 659
Palmer, J.P., 172, 1211
Pantò, F., 310
Papa, V., 1579
Papachristou, D.N., 752
Papacostas, J.S., 597

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

Parker, J., 1123
 Paro, M., 1023
 Patel, Y.C., 752
 Peck, A.B., 894
 Pedersen, O., 1343
 Pederson, R.A., 1390
 Peig, M., 1396
 Pek, S.B., 1371
 Pelkonen, R., 641
 Persson, B., 1271
 Peters, E.J., 328
 Peterson, R.G., 373
 Pettitt, D.J., 435
 Pham, K., 752
 Phillips, L.S., 70, 758
 Pietrzyk, R.A., 328
 Pinault, S., 304
 Pinkert, C., 1056
 Plurad, S.B., 569
 Polonsky, K.S., 1549
 Pontieri, G.M., 1478
 Popiela, H., 146
 Pories, W.J., 1217
 Porte, D., Jr., 562, 1333
 Portha, B., 610
 Powell, W.J., Jr., 1585
 Pratten, M.K., 773
 Prince, M.J., 328
 Prochazka, M., 1446
 Proctor, G.B., 1381
 Prosdocimi, M., 1023
 Province, M.A., 1258
 Puech, A.J., 1161
 Pugliese, G., 1258
 Pujol-Borrell, R., 1396
 Purrelio, F., 1417
 Pyörälä, K., 1307

Q
 Quyyumi, A.A., 1585

R
 Rabinowicz, S.L., 938
 Raboudi, S.H., 975
 Rajan, A.S., 188, 874
 Rajotte, R.V., 1133
 Ramachandran, J., 987
 Ramanadham, S., 1390
 Rand, L.I., 460
 Rao, L.V.M., 212
 Rapoport, S.I., 1469
 Rateri, D.L., 1484
 Rau, K., 39
 Ravussin, E., 1423
 Reach, G., 164
 Reaven, G.M., 1155
 Recant, L., 691
 Reddy, K., 31
 Reich, E.-P., 1647

Rendell, M., 819
 Reymond, M.J., 471, 1351
 Ribes, G., 1291
 Ricker, A.T., 358
 Ricordi, L., 589
 Rillaerts, E.G., 1412
 Rizza, R.A., 97, 291
 Roberts, C.T., Jr., 428
 Robertson, R.P., 44, 58, 671, 1439, 1501
 Rodriguez, N.R., 847, 1238
 Rodriguez-Gil, J.E., 793
 Rogus, E., 333
 Roseman, J.M., 629
 Rosen, O.M., 1508
 Ross, G.R., 257
 Rossetti, L., 648
 Rossi, G.L., 471, 1301, 1351
 Rossi, M., 589
 Rossini, A.A., 24
 Rowley, W.H., 1337
 Ryan, C.A., 1585

S
 Sacks, D.B., 84
 Sadler, T.W., 70
 Sai, P., 634
 Saito, N., 1005
 Saitoh, Y., 1005
 Sakamoto, N., 91
 Samà, B., 75
 Sane, T., 580
 Sanz, N., 17
 Sapienza, N., 310
 Satake, T., 231
 Sato, Y., 91
 Scarantino, G., 718
 Scarling, D., 1647
 Scharfmann, R., 686
 Scharpf, D.W., 386, 422, 808, 1478
 Schatz, D., 534
 Schiavivato, A., 1012
 Schmidt, R.E., 569, 959
 Schmitz, O., 1343
 Schoenfeld, S.L., 172
 Schonfeld, G., 604
 Schwartz, M.W., 562
 Schwenk, W.F., 97, 847, 1238
 Seaquist, E.R., 1439
 Seddio, G., 718
 Segain, J.-P., 634
 Segal, K.R., 1165
 Semplicini, A., 75
 Serie, J.R., 146, 1148
 Serio, M.K., 219
 Serreze, D.V., 1446
 Sethu, S., 31
 Sevestre, H., 634
 Share, L., 54
 Sherman, W.M., 854
 Sherman, W.R., 569, 1258
 Sherwin, R.S., 1193, 1647
 Shigeta, Y., 832

T
 Taborsky, G.J., Jr., 562

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

AUTHOR INDEX 1989

Tahara, D., 1573
Takahashi, K., 1200
Takayama-Hasumi, S., 663
Tanaka, C., 1005
Tani, S., 1042
Taniguchi, H., 1005
Tarui, S., 902
Taskinen, M.-R., 580
Taub, R., 31, 123
Teague, J., 625
Terada, M., 832
Teruya, M., 1329
Tewari, D.S., 31
Thacker, S.V., 237
Thériault, G., 304
Thevenot, D.R., 164
Thomas, D.C., 1103
Thomas, L.J., 659
Thomas, T.P., 1371
Thomassen, A., 1175
Thorburn, A.W., 499
Thulin, A., 1381
Thunberg, L., 764
Tilton, R.G., 569, 1258, 1484
Timmers, K.I., 691
Toffolo, G., 1048
Tontis, D.K., 1301
Travers, J.P., 773
Tremblay, A., 304
Trevisan, R., 75
Triban, C., 1012
Triolo, G., 718
Trischitta, V., 1579
Trucco, G., 1617
Trucco, M., 1617
Tsushima, T., 1090
Turk, J., 1251
Turtle, J.R., 257

U
Uchigata, Y., 663
Umpierrez, G.E., 758
Uriu-Hare, J.Y., 1282
Uusutupa, M., 1307

V
Valentin, A., 634
Van Camp, K.M., 1412
Van Der Burg, M.P.M., 1082

Van Der Hoop, R.G., 225
Van Der Zee, C.E.M., 225
Van Haastert, F.A., 1082
Van Wyk, J.J., 710
Vardi, P., 358, 1320
Varini, M., 1301
Velasquez, M.T., 679
Velho, G., 164
Velussi, M., 75
Vetri, M., 1417
Vigneri, R., 1417, 1579
Vinik, A.I., 1097
Vinson, J.A., 1036
Virmelli, S., 1433
Vizzaccaro, A., 75
Von Schenck, H., 1357
Voorbij, H.A.M., 1623
Voyle, N.R., 691

W
Wadhwan, K.C., 1469
Wagenknecht, L.E., 629
Wahrenberg, H., 524
Walczak, K., 244
Wallace, L.J., 278
Wallace, P., 1549
Wallberg-Henriksson, H., 906
Walseth, T.F., 44, 1439
Ward, W.K., 562
Warne, G.L., 779
Warnock, G., 1133
Warram, J.H., 460
Wasserman, D.H., 484, 799
Watanabe, N., 902
Watanabe, Y., 231
Walters, K., 1528
Weigle, D.S., 925
Weik, H., 1056
Weinhaus, A.J., 1148
Weir, G.C., 49, 338
Weiss, M., 454
Welsh, M., 1377
Welsh, N., 1377
Werther, G.A., 779
West, D.B., 159
Whalen, L.R., 730
Wilford, M., 1544
Wilkin, T.J., 172
Wilkins, S., 691
Williams, G., 321
Williams, J.A., 182, 544

Williams, P.E., 7, 484
Williamson, J.R., 569, 1258, 1484
Woehrle, M., 1402
Wolf, B.A., 1251
Wolfe, J.A., 435
Wong, C.Y., 1117
Worthen, S.M., 1446
Wright, J.R., Jr., 379
Wu, F.-S., 333
Wynn, R.E., 70

X
Xiang, K.-S., 17

Y
Yabuuchi, M., 723
Yagi, J., 1647
Yamaguchi, Y., 1573
Yamamoto, H., 1573
Yamanouchi, T., 723
Yamashita, M., 832
Yamazaki, H., 1573
Yao, K., 663
Yasuda, H., 832
Yki-Järvinen, H., 580, 744
Yokota, A., 1496
Yoon, J.-W., 316
Yorek, M.A., 996
Yoshimura, A., 1109
Yoshioka, N., 262
Young, A.A., 744
Yue, D.K., 257

Z
Zambito, A.M., 310
Zellner, K., 123
Zeng, Q.-H., 219
Zhang, H.-J., 44
Zhang, W.-X., 1023
Ziegler, A.G., 358, 1320
Ziegler, R., 1320
Zierler, K., 333
Zimmerman, T., 1238
Zimmet, P.Z., 1602
Zingg, H.H., 752
Zurlo, F., 1423

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

Subject Index

A

Abscess, 659
Acanthosis nigricans, 328
Acetylcholine
 cardiomyopathy marker, 231
 stimulation of insulin release, 198
Acute metabolic acidosis, 847
Acyl-CoA:cholesterol acyltransferase, 604
Adenine nucleotide translocator, 1377
Adenosine effect on pancreas, 1291
Adenylate cyclase, phosphatidic acid effects, 1187
Adipocytes
 insulinlike growth factor I, 1217
 obese rate of glucose transport, 991
 prostaglandin I_2 production, 1123
Adoptive transfer, 447
Aging effects on insulin secretion, 1549
Albumin permeation, 1258, 1484
Albuminuria, 981
Aldose reductase inhibitors
 ascorbic acid pathways, 257
 glomerular abnormalities, 981
 hemodynamic and vascular changes, 1258
 kidney, 1067
 nephropathy pathogenesis, 839
 nerve edema prevention, 1469
 neuropathy treatment comparison, 832
 ponalrestat effects on rat retinas, 1181
 sorbinil effects, 569
Alkalosis, 847
Allograft rejection, islet protection, 379
Allotransplantation, 146
Alloxan-induced diabetes in rabbits, 1484
Amino acid, infusion and glomerular filtration rate, 75
Amylin, 1333
 antigen, 64K, 1133
Antidepressants, 1161
Anti-single-stranded-DNA antibodies, 718
Apolipoprotein gene, Chinese Americans, 17
Arachidonic acid, 1123
Ascorbic acid, 257, 1036
Aspirin effects on retinopathy, 491
Atherosclerosis, 117
 chylomicrons effect, 141
 -like lesions, 91
ATP-sensitive K^+ channels, 416, 422
Autonomic function tests, 589
Autoregulation of renal blood flow, 1109
Azathioprine, 779

B

Baboons, 925
BB rat. *See Rats*
Blood
 flow, aldose reductase inhibitor effects, 1258
 -nerve barrier permeability-surface area product, 1469
 viscosity, fish oil effects, 1412
Body fat distribution, 304
Bone marrow transplantation, 894
Brain
 counterregulation of hypoglycemia, 7
 somatostatin accumulation, 752

C

Ca^{2+}
 cAMP rise effect, 874
 insulin release
 acetylcholine stimulation, 198
 voltage-dependent channels, 188
 phosphatidic acid effects, 1187
Caco-2 cell line, 604
Calmodulin, 84
cAMP metabolism
 HIT cells, 44
 increase effect on Ca^{2+} influx, 874
Capillary
 basement membrane, 854
 thickness, 1245
 density, 854, 1245
Carbachol-enhanced insulin release, 1337
Carbohydrates, kidney function and structure, 679
Carcinoid tumors, 667
Cardiomyopathy
 ω -3 fatty acid effects, 969
 markers, 231
 preinfarction risk factors, 350
Cardiovascular disease, risk factors, 504
Carnitine palmitoyltransferase, 65
Catecholamines
 decreased with posture change, 938
 ketone bodies, 454
 lipolysis, 524
 sympathochromaffin activity, 405
 β -Cell
 cAMP rise effects, 874
 deficiency, insulin and glucagon pulse amplitude decrease, 925
 depolarization, Ca^{2+} channels, 188
 electrical activity, 416

encephalomyocarditis virus effects, 1103

function, 1056
 insulin secretion, 673
 islet cell antibodies, 1396
interleukin 1 concentration, 1211
high-glucose effects on insulin secretion, 1417
MHC molecule hyperexpression, 815
pancreas, compensatory growth, 49
retinoid effects, 1544
Cellular retinoid-binding proteins, 1544
Ceruletide, β -cell secretory responsiveness, 1042
Children, azathioprine effects, 779
Chinese Americans, 17
Cholecystokinin-enhanced insulin release, 1337
Cholesterol
 effect of growth factors on retention, 117
 ester synthesis and secretion, 604
 free, high-density lipoprotein abnormalities, 1226
 gastrectomy, 219
 synthesis, 141
Chylomicrons, 141
c-myc, cellular growth, 123
Collagen production, 758
Compensatory growth, glucose infusion, 49
Confocal microscopy, 808
Coronary artery disease and insulin, 1175
Cortisol and growth hormone effect on insulin resistance, 1357
C-peptide secretion, 698
Cross correlation, 589
Cross-reactivity, 718
Cryopreservation
 human fetal pancreas, 448
 human islet storage, 386
Cyclophosphamide-induced diabetes, 441, 1492
Cyclosporin
 effect on T-lymphocyte parameters, 249
 insulin secretion, 465, 698
multiple sclerosis, 58

D

Dawn phenomenon, 273, 1193
Deep breathing, 589

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

Deferoxamine therapy, 1207
 Dendritic cells, 1623
 Desferrioxamine, islet protection, 379
 Diabetic macroangiopathy. *See*
 Macroangiopathy
 Diacylglycerol, endothelin effects on, 1643
 Diet
 fiber effects on glucose/lipid levels, 1528
 maternal Zn intake, 1282
 treatment effects, 262
 Dimethyl sulfoxide, modulation of onset, 194
 Dipyridamole and aspirin in retinopathy, 491
 Disease-association studies, 947
 Diuresis, 278
 DMSO. *See* Dimethyl sulfoxide
 Dogs
 cyclosporin effects, 698
 exercise-induced glucagon rise, 799
 insulin fall, 484
 hypoglycemia, 7
 leucine metabolism, 847
 pancreatectomy, 861
 partial, 1082
 Duct obliteration, 1082
 Dystrophy, neuroaxonal, 569

E
 ELISA. *See* Enzyme-linked immunosorbent assay
 Embryopathy, 70
 Encephalomyocarditis virus, 316, 1103
 Endothelial cells
 adipocyte-released arachidonic acid, 1123
 insulinlike growth factors, 710
 number, 1245
 permeability in rabbit hearts, 1484
 production of endothelin, 1200
 Endothelin effects in retinal capillary pericytes, 1643
 Endothelium and high-glucose exposure, 212
 Enzyme-linked immunosorbent assay (ELISA)
 displacement comparison of insulin autoantibodies, 1275
 Epinephrine
 increased sensitivity to, 405
 inhibited glucose absorption, 410
 Epitope presentation, 868
 Erythrocytes
 ascorbic acid, 1036
 glucose homeostasis, 410
 membrane lipid peroxidation, 1539
 Na⁺-pumping activity, 825
 vitamin B₆ effects, 881
 Ethnic groups
 Chinese Americans, 17

Hispanics, 123
 Mexican Americans, 975
 Nauruans, 1602
 Pima Indians, 435, 1423
 Exercise
 capillary basement membrane thickness, 854
 fall in insulin, 484
 glucagon increase, 799
 lipolytic response, 524

F
 Fat feeding, 499
 ω-3 Fatty acids
 cardiac performance and plasma lipids, 969
 fish oil effects
 atherosclerotic disease, 539
 glucose and lipid metabolism, 1314
 hyperglycemia, 1402
 lipid values and hemorheological parameters, 1412
 Fatty acids, free
 evening insulin, 580
 insulin resistance, 906
 lipolysis regulation, 1595
 metabolism and exercise, 484
 d-Fenfluramine, 499
 Ferritin, 1207
 Fish oil. *See* ω-3 fatty acids
 Free fatty acids. *See* Fatty acids, free
 Free radicals, islet protection, 379

G
 Galanin, 1114
 Ganglioside, 1012, 1478
 Gastrectomy, 219
 Gemfibrozil, 364
 Genetics
 association studies, 947
 development of non-insulin-dependent diabetes, 17
 inbred BB/Wor rats, 887
 linkage with loci, 653
 nonobese diabetic mice, 1446
 Pima Indian
 insulin receptors, 1496
 insulin resistance, 1423
 Glomerular
 basement membrane, 839
 filtration rate
 aldose reductase inhibitors, 981, 1258
 ketone body infusion, 75
 structure, 1142
 Glucagon
 effects on hepatocytes, 793
 -like peptide, 338, 902, 1534
 pulse amplitude decrease, 925

secretion, 562, 861
 synthase, 1343
 Glucocorticosteroids, 1238
 Gluconeogenesis
 basal insulin supplementation, 291
 increased hepatic glucose production, 550
 sleep, 285
 Glucose
 conversion to lactate, 237
 counterregulation, 1193
 defective, 405
 desensitization, 1417, 1501
 isotopic measurement, 744
 levels
 dietary fiber effects, 1528
 high, effects, 212, 1326, 1417
 neuroblastoma cells, 996
 polymorphonuclear leukocyte function, 1031
 metabolism
 basal insulin supplementation, 291
 fish oil supplementation, 1314
 conversion to lactate, 237
 parasympathetic nervous system, 1433
 sleep effects, 285
 oxidation, interleukin 1 effects, 1251
 phasic effect on insulin secretion, 625
 production, 97
 basal insulin supplementation, 291
 gluconeogenesis role, 550
 evening insulin, 580
 obese children, 477
 rate measurement, 744
 sleep effects, 285
 regulation, 1082
 sensors, needle-type, 164
 tolerance, 1512
 body fat distribution, 304
 galanin effects, 1114
 impaired, evaluation of criteria, 1630
 interferon effect, 641
 intravenous, 58
 sexual dimorphism, 159
 test, 1048
 transport
 chromosomal localization, 1072
 erythrocyte role, 410
 glyburide effects, 205
 insulinlike growth factor I, 1217
 obesity effects, 991
 SHR rats, 1155
 sialic acid, 951
 turnover, 97, 477, 499
 utilization, 97
 Glyburide, effect on glucose transport, 205
 Glycemic control
 dietary treatment, 262
 plasma 1,5-anhydro-D-glucitol as marker, 723
 urinary growth hormone, 1567
 Glycogen synthase, 793

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

Glycolipids in islets, 1478
 Glycosylated hemoglobin, 1539
 Glycosylation
 polymorphonuclear leukocyte function, 1031
 role in glucose desensitization, 1417
 Gonadotrophs, 1301
 G proteins
 insulin secretion, 1439
 receptor-effector coupling prevented, 1611
 Growth hormone, 428
 and cortisol on insulin resistance, 1357
 galanin effects, 1114
 urinary, 1567

H

HDL. See Lipoproteins, high-density
 Heart-rate variability, 589
 Hemochromatosis, 1207
 Heparan sulfate, 130, 718
 Hepatic glucose production, 550, 1433
 Hindquarter metabolism, 597
 Hispanics, retinopathy risk factors, 1231
 HIT cells
 cAMP levels, 874
 insulin secretion 44, 625, 1439
 HLA-DR4 patients, 942
 Human
 adipose tissue and insulinlike growth factor, 710
 fetal pancreas islet isolation, 917
 insulin autoantibody, 663
 leukocyte antigen DQw8, 942
 Hyperglycemia
 amylin biosynthesis stimulated, 1333
 fish oil effects, 1402
 insulin secretory patterns, 691
 pancreatic islets, 410
 retinopathy, 1200
 sexual dimorphism, 159
 Hyperinsulinism
 fetal, 597
 glucose turnover, 97
 macroangiopathy, 91
 Hyperplasia, compensatory growth, 49
 Hypertriglyceridemia, treatment, 364
 Hypertrophy, compensatory growth, 49
 Hypoglycemia
 brief exposure during organogenesis, 1573
 counterregulation, 7
 epidemiology, 1193
 insulin resistance, 1357
 maternal, teratogenic, 1063
 risk factors, 1193
 unawareness, 405, 1193
 Hypothalamus
 mediobasal, 471, 1351
 neuropeptide Y concentrations, 321

I
 IDDM. See Insulin-dependent diabetes mellitus
 IGF-I. See Insulinlike growth factor I
 Immunogenicity, 146
 Impaired glucose tolerance, evaluation of criteria, 1630
 Incidence
 nonobese diabetic mice, 1296
 Pima Indians, 435
 myo-Inositol metabolism, 996
 Insulin
 antibody
 early detection, 1557
 immune complex, 343
 humoral response, 868
 autoantibodies
 comparison by precise displacement ELISA, 1275
 heterogeneity, 1090
 life-table analysis of progression, 1320
 measurement, 172
 risk increase, 358
 autoimmune syndrome, 663
 binding, gliburide effects, 205
 cellular growth, 123
 cholesterol
 esterification, 504
 retention, 117
 chronic deficiency, 610
 coronary artery disease, 1175
 degradation, 152
 exercise-induced fall, 484
 fetal metabolism, 597
 free-fatty acid suppression, 580
 history, 1
 hyperpolarization, 333
 immune complex, 343
 infusion, glucose turnover, 97
 injection, macroangiopathy, 91
 lipolysis regulation, 1595
 low levels and embryos, 773
 mixed muscle protein synthesis, 618
 mRNA, 1377
 myofibrillar proteolysis, 1117
 pulse amplitude decrease, 925
 requirements, 273
 resistance
 acanthosis nigricans, 328
 catecholamines effect, 906
 dawn phenomenon, 273
 fenfluramine effects, 499
 growth hormone and cortisol effects, 1357
 insulin-receptor gene, 31
 nicotinic acid, 562
 obese patients, 477, 1579
 Pima Indians, 1423, 1496
 polycystic ovary syndrome, 1165
 prednisone therapy, 1238
 SHR rats, 1155
 variants in non-insulin-dependent diabetes, 784

ribosomal protein S6 kinase activated, 544
 secretion
 aging effects, 1549
 ATP-sensitive K⁺ channels, 416, 422
 azathioprine effects, 779
 biphasic pattern, 625
 Ca²⁺ effects, 198
 β-cell
 function, 673, 1377
 secretory capacity, 562
 secretory responsiveness, 1042
 cyclosporin effect, 465, 698
 glucagonlike peptide, 338, 1534
 high-glucose effects, 1417
 HIT cells, 44, 1439
 hyperglycemia, 510
 impaired, 1377
 interleukin 1 effects, 1251
 neonatal development, 1337
 nimodipine, 188
 pancreatectomy, 861
 patterns compared, 691
 phosphatidic acid effects, 1187
 βII-protein kinase C, 1005
 protein kinase C role, 1371
 retinoids, 1544
 sulfonamides effects, 422
 sensitivity
 interferon effect, 641
 intravenous glucose tolerance test, 1048
 lithium effect, 648
 variants in non-insulin-dependent diabetes, 784
 sialic acid effect, 951
 systemic delivery, 1082
 therapy
 effect on rat retinas, 1181
 interrupted in pregnancy, 764
 somatostatin analogue effects, 704
 Insulin-dependent diabetes mellitus
 anti-single-stranded-DNA antibody cross-reactivity, 718
 carcinoid tumors, 667
 catecholamine-induced lipolysis, 524
 children, azathioprine effects, 779
 comparison of insulin autoantibodies, 1275
 cyclosporin effects, 249
 dendritic cells, 1623
 epinephrine, increased sensitivity to, 405
 glomerular
 filtration rate, 75
 structure, 1142
 high- and low- in nonobese diabetic mice, 1296
 high-density lipoprotein abnormalities, 1226
 human leukocyte antigen -DQ as susceptibility marker, 1617
 -DQw8, 942
 hypoglycemia, 1193

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139
 February, 141-271
 March, 273-404

April, 405-538
 May, 539-669
 June, 671-814

July, 815-945
 August, 947-1075
 September, 1077-1202

October, 1203-1331
 November, 1333-1500
 December, 1501-1651

interleukin, 1, concentration, 1211
 interleukin, 2, production, 310
 islet cell antigen expression, 1326
 kidney transplantation, 516
 life-table analysis of progression, 1320
 lipolysis regulation, 1595
 lymphokine production, 310
 major histocompatibility complex molecule hyperexpression, 815
 mixed muscle protein synthesis, 618
 Na^+ -pumping activity, 825
 newly diagnosed antibody detection, 1557
 β -cell function and islet cell antibodies, 1396
 pathogenesis, 534
 in rats, 267
 virus role, 316
 platelet activation, 1097
 prediabetic screening, 1462
 remission, azathioprine effects, 779
 retinopathy risk factor, 450
 rosettes as markers, 634
 scavenger macrophages, 1623
 siblings, elevated proinsulin, 1271
 64K antigen identified, 1133
 somatostatin analogue effects, 704
 yellow fever vaccine, 1636
 zinc-dependent low thymic hormone level, 932

Insulin receptor
 autoantibodies to, 1090
 biosynthesis, 182
 downregulation, 182
 function, 1508
 gene
 Chinese Americans, 17
 insulin resistance, 31
 linkage, 653
 marker for non-insulin-dependent diabetes, 737
 Mexican Americans, 975
 Pima Indians, 1496
 internalization defects, 1579
 kinase
 calmodulin, 84
 defective mechanism, 397
 in vivo insulin action, 108
 sulfonylurea effects, 1343
 mRNA levels, 182
 radioimmunoassay, 987
 structure, 1508

Insulinlike growth factor
 action and production in human adipose tissue, 710
 binding protein, 710, 1573
 cellular growth, 123
 cholesterol retention, 117
 collagen production, 758
 fetal islet cells, 686
 glucose transport, 1217
 growth hormone effect, 428
 receptors, 710, 1217

Insulinoma, 1333
Insulitis
 genetic development, 1446
 islet protection, 379
Interferon
 activity and yellow fever vaccine, 1636
 encephalomyocarditis virus effects, 1103
 glucose tolerance and insulin sensitivity, 641
Interferon- γ , 911
Interleukin 1
 high-glucose effects, 212
 prostaglandin E_2 accumulation, 1251
 target-cell activity effects, 1211
Interleukin 2
 cyclosporin effects, 249
 production in insulin-dependent diabetes, 310
Intermittent claudication, 405
Intravenous glucose tolerance test, 1048
Iron metabolism, 1207
Ischemia in rabbit hearts, 1484
Islets
 amyloid polypeptide, 1333
 cell
 antibodies, 667, 1320, 1396
 antigen expression, 1326
 cytotoxicity, 1329
 insulin release stimulated, 1371
 human fetal pancreas isolation, 917
 protection from immune destruction, 379
 transplantation, 146, 244, 1148
 see also Pancreas, islets
Islets of Langerhans
 β -cell activity, 1211
 cryogenic storage, 386
 pancreatic diabetes, 1
 three-dimensional imaging, 808
 transplantation, 244
IVGTT. See Intravenous glucose tolerance test

K

Ketoacidosis and prostacyclin production, 1585
Ketogenesis increased by exercise, 799
Ketone body
 infusion and glomerular filtration rate, 75
 kinetics, 454
Kidney
 aldose reductase inhibition effects, 981
 function and high carbohydrate intake, 679
 transplantation, 516

L

Lactate production, 237
Laser Doppler techniques, 819

Leprechaunism, 31
Leucine
 glucocorticosteroid therapy, 1238
 metabolism, 847
 nonglucose stimulator, 1211
Life-table analysis of progression to diabetes, 1320
Lipids
 dietary fiber effects on levels of, 1528
 membrane alterations, 825
 metabolism
 fish oil effects, 1314, 1412
 interrupted insulin treatment, 764
 peroxidation, 1539
Lipolysis, 454, 524, 1595
Lipoproteins
 high density
 compositional abnormalities, 1226
 receptor activity decrease, 117
Lithium effect, 648
Lobenzarit, 558
Lovastatin, 364
Luteinizing-hormone releasing hormone, 471
Lymphokine, production in insulin-dependent diabetes, 310
Lymphopenia, 887
Lysophospholipids, 625

M

Macroalbuminuria, Nauru, 1602
Macroangiopathy, 91
Macrophages
 fish oil inhibition, 1402
 islet cell cytotoxicity, 1329
 scavenger, 1623
Macula densa, 75
Major histocompatibility complex
 antigen expression, 911
 class II
 allograft transplantation, 146
 pathogenesis of diabetes in rats, 267
 hyperexpression of molecules, 815
 interferon- γ , 911
Malformations, embryopathy, 70
Markers
 cardiomyopathy
 acetylcholine, 231
 norepinephrine, 231
 glycemic control
 plasma 1,5-anhydro-D-glucitol, 723
 insulin-dependent diabetes
 human leukocyte antigen-DQ, 1617
 rosettes, 634
Meal phenomenon, 273
Mediobasal hypothalamus, 471, 1351
Mesangial expansion, 1077
Mexican Americans, 975
MHC. See Major histocompatibility complex
Mice
 abscess, 659

DIABETES: VOLUME 38 (1989) PAGE NUMBERS BY ISSUE

January, 1-139	April, 405-538	July, 815-945	October, 1203-1331
February, 141-271	May, 539-669	August, 947-1075	November, 1333-1500
March, 273-404	June, 671-814	September, 1077-1202	December, 1501-1651

CD-1, inhibition of diabetes, 558
β-cell
 encephalomyocarditis virus, 1103
 failure, 815
 function, 1056
diabetogenic viral gene, 316
dietary fiber, 1528
hyperglycemia, 510, 1402
islets, insulin release, 198
muscarinic stimulation, 1433
nonobese diabetic (NOD)
 bone marrow transplantation, 894
 comparison of high- and low-
 diabetes incidence, 1296
cyclophosphamide-induced diabetes,
 441, 1492
dimethyl sulfoxide modulation of
 onset, 194
genetics, 1446
insulin autoantibodies, 358
prevention by T-lymphocyte injection,
 1647
obese, muscarinic stimulation, 1433
Microalbuminuria, Nauru, 1602
Microvascular
 changes in skin, 819
 structure and vasoactive behavior,
 1245
Mixed muscle protein synthesis, 618
Monkeys, peripheral neuropathy, 1365
Multiple sclerosis
 cyclosporin, 58
Muscarinic
 receptors, 1611
 stimulation, 1433
Myocardial infarction, 350
Myofibrillar proteolysis, 1117

N
Na⁺-K⁺ pump activity, 996
National Diabetes Data Group criteria for
 impaired glucose tolerance, 1630
Nauru, micro- and macroalbuminuria risk
 factors, 1602
Nephropathy
 autoregulation of renal blood flow,
 1109
 glomerular structure, 1142
 high carbohydrate intake, 679
 mesangial expansion, 1077
 renal aldose reductase activity, 1067
 transplanted kidneys, 516
Nerve
 conduction velocity, 225, 1307, 1365
 edema prevention, 1469
 regeneration, 1012
Neuroblastoma cells, 996
Neuropathy
 autonomic, 405, 938
 abnormal response of parotid gland,
 1381
 bladder function, 1012
 tyrosine hydroxylase activity, 959

epidemiological correlates, 1456
ganglioside treatment, 1012
peripheral
 central nervous system dysfunction,
 730
 monkeys, 1365
 peptide treatment, 225
 prevalence in newly diagnosed
 patients, 1307
 study in rats, 373
 treatment comparison, 832
Nicotinamide, islet protection, 379
Nicotinic acid, 562
NIDDM. See Non-insulin-dependent
 diabetes mellitus
Nimodipine, 188
NOD mice. See Mice, nonobese diabetic
Non-insulin-dependent diabetes mellitus
 basal insulin supplementation, 291
β-cell secretory responsiveness, 1042
 comparison of insulin autoantibodies,
 1275
dietary treatment, 262
 fish oil supplementation, 1314
evening insulin, 580
ferritin levels, 1207
genetic variations, 17
gluconeogenesis, 550
glucose desensitization, 1501
high carbohydrate intake, 679
hyperglycemia, 1333
hypertriglyceridemia treatment, 364
insulin receptor
 genetic defects in Pima Indians,
 1496
 internalization defects, 1579
 kinase activity, 397
insulin-sensitive/-resistant variants, 784
iron metabolism, 1207
linkage, 653
lithium effect, 648
markers
 plasma 1,5-anhydro-D-glucitol, 723
 restriction-fragment-length
 polymorphism, 737
 Mexican Americans, 975
Na⁺-pumping activity, 825
neuropathy in newly diagnosed
 patients, 1307
parasympathetic nervous system, 1433
retinopathy, proliferative, 435
sexual dimorphism, 159
sulfonylurea effects on skeletal muscle,
 1343
 vitamin B₆ effects, 881
Norepinephrine
 cardiomyopathy marker, 231
 ketogenic and lipolytic effects, 454
Nutrition, collagen production, 758

O
Obesity
 basal insulin supplementation, 291

body-fat distribution, 304
children, 477
glucose conversion to lactate, 237
glucose transport rate, 991
polycystic ovary syndrome, 1165
sexual dimorphism, 159
2',5'-Oligoadenylate synthetase and
 interferon activity, 1636
Onset of diabetes
 dimethyl sulfoxide modulation,
 194
Oral glucose tolerance test, 1630

P
Pancreas
diabetes, 1
glucagon secretion, 1291
islets
 adaptation, 562
 ATP-sensitive K⁺ channels, 422
β-cell function, 58, 1056
cryogenic storage, 386
fetal and insulin-like growth factor I,
 686
ganglioside expression, 1478
hyperglycemia, 510
isolation of human fetal, 917
mRNA expressed, 1377
64K antigen identified, 1133
rats
 acini, S6 phosphorylation, 544
 adenosine effect, 1291
 glucagon-like peptides, 338, 902
 somatostatin accumulation, 752
 transplantation, 448, 1082
Parasympathetic nervous system and
 glucoregulation, 1433
Parotid salivary gland, 1381
Pathogenesis
 insulin-dependent diabetes mellitus,
 534
 in mice, 267
 virus role, 316
Pericytes, function in the retina, 1200,
 1643
Phosphatidic acid effects, 1187
Phosphoinositide
 hydrolysis, phosphatidic acid effects,
 1187
 turnover, 1097
Phosphorylation, 84, 328, 544
Pima Indians
 insulin receptors, 1496
 insulin resistance, 1423
 proliferative retinopathy, 435
Pituitary hormone secretion
 gonadotropin, 1301
 neuropeptide Y concentrations, 321
 thyrotropin, 1301, 1351
Placental insulin, 39
Plasma 1,5-anhydro-D-glucitol as
 glycemic control marker, 723
Platelet activation, 1097

Polycystic ovary syndrome, 1165
 Polymorphonuclear leukocyte function, 1031
Polyol
 accumulation by neuroblastoma cells, 996
 ascorbic acid metabolism, 257
Postprandial glucose metabolism
 basal insulin supplementation, 291
Posture, 938
Prediabetic screening, 1462
Prednisone and insulin resistance, 1238
Pregnancy
 dietary Zn effects, 1282
 hypoglycemia, 1063
Prevention of diabetes
 spleen cell transfusion, 24
 T-lymphocyte injection, 1647
Proinsulin
 dietary treatment effects, 262
 disproportionate increase/release, 1333
 elevated levels in siblings, 1271
Proliferative retinopathy. See
 Retinopathy, proliferative
Propranolol effect on insulin resistance, 1357
Prostacyclin production and ketoacidosis, 1585
Prostaglandin
 E₁ effect on neuropathy, 832
 E₂ effect on insulin secretion, 1251, 1439
 I₂ production, 1123
Protein kinase C
 endothelin effects, 1643
 glyceraldehyde activation, 1371
 β II subspecies, 1005
Proteoglycan, 130

R

Rabbits, alloxan-induced diabetes, 1484
Radioimmunoassay, 987
Rats
 BB
 dendritic cells and scavenger macrophages, 1623
 urinary bladder function, 1023
 BB/Wistar
 carnitine palmitoyltransferase, 65
 pathogenesis of diabetes, 267
 ponalrestat effects on retinas, 1181
 BB/Wor
 inbred genetic study, 887
 islet transplantation, 1148
 spleen cell transfusion, 24
 cardiomyopathy markers, 231
 embryo, brief hypoglycemic exposure, 1573
 fenfluramine effects, 499
 galactosemic, nerve edema prevention, 1469

gastrectomy, 219
 glucagonlike peptide I effects, 1534
 glucose
 homeostasis and erythrocytes, 410
 sensors, 164
 hyperinsulinism, macroangiopathy, 91
 hypoglycemia, maternal, 1063
 insulin
 -gene expression, 39
 low levels and embryonic growth, 773
 neonatal release development, 1337
 -receptor kinase activity, 108
 secretory patterns, 691
 islets
 allotransplantation, 146
 cell antigen expression, 1326
 glucose metabolism effects, 1417
 Langerhans β -cell activity, 1211
 phosphatidic acid effects, 1187
 transplantation, 1148
 L_A/N-cp, insulin secretory patterns, 691
 lithium effect, 648
 Lou/M
 humoral immune response, 868
 insulin antibodies, 343
 maternal dietary Zn intake, 1282
 nerve edema prevention, 1469
 neuropathy
 and central nervous system dysfunction, 730
 peptide treatment, 225
 nude, islets transplantation, 244
 pancreas
 glucagonlike peptides, 338, 902, 1534
 islets, β II-PKC, 1005
 phosphorylation, 84, 544
 placental insulin, 39
 prostaglandin I₂ production, 1123
 ribosomal protein S6 kinase activity, 544
 serotonin-uptake blockers, 1161
 SHR, insulin resistance, 1155
 SHR/N-cp
 high carbohydrate intake, 679
 insulin secretory patterns, 691
 skeletal muscle, 84, 333, 906
 sorbinol effects, 839
 teratogenicity, 1282
 tricyclic antidepressants, 1161
 urinary bladder dysfunction, 278
 vasoressin, 54
 Wistar
 chronic insulin deficiency, 610
 glucose conversion to lactate, 237
 hyperinsulinism, 91
 neuropathic study, 373
 sexual dimorphism, 159
 yolk sac insulin, 39
 Zucker
 exercise, 854

see also Streptozocin-induced diabetes mellitus
 Remission, azathioprine effects, 779
Restriction-fragment-length polymorphism
 development of non-insulin-dependent diabetes, 17
 link to chromosome 17 markers, 1072
 marker for non-insulin-dependent diabetes, 737
 Mexican Americans, 975
Retinal
 capillaries
 endothelin effects, 1643
 ponalrestat effects, 1181
 endothelial cells production of endothelin, 1200
 pericyte function, 1200
 see also Retinopathy
Retinoids, 1544
Retinopathy
 aspirin effects, 491
 background, progression, 460
 pathogenesis, 1203
 proliferative, Pima Indians, 435
 risk factors, Hispanics, 1231
 urinary growth hormone as measurement, 1567
RFLP. See *Restriction-fragment-length polymorphism*
RINm5F cells
 antibody detection, 1557
 insulin release, 1371
 retinoid effects, 1544
 interferon- γ effects, 911
Risk factors
 cardiovascular disease, 504
 hypoglycemia, 1193
 micro- and macroalbuminuria, 1602
 myocardial infarction, 350
 neuropathy, 1456
 overt diabetes, 358
 retinopathy, 435, 460, 1231
 Rosettes as markers, 634

S

Sandostatin, 704
Sarcoplasmic reticulum, 969
Serotonin-uptake blockers, 1161
Sexual dimorphism, 159
Sialic acid, effect on glucose transport, 951

Skeletal muscle
 catecholamines effect, 906
 fractional mixed protein synthesis, 618
 hyperpolarization, 333
 phosphorylation, 84
 proteolysis, 1117
 sulfonylurea effects, 1343
Skin, microvascular changes, 819
Sleep, effects on glucose production, 285

Small intestine
gastrectomy, 219
hypercholesterolemia, 141

Somatostatin
analogue effects, 704
 β -cell activity inhibitor, 1211
glucagonlike peptide I effects, 1534
insulin resistance, effect on, 1357
tissue-specific alterations, 752

Somogyi phenomenon, 1193

Sorbitol, 569
glomerular structure, 839
myo-inositol metabolism, 996

Sorbitol, 1036

S6 phosphorylation in pancreatic acini, 544

Streptozocin-induced diabetes mellitus
baboons, 925
mice, fish oil effects, 1402
rats
adenosine effects in pancreas, 1291
aldose reductase inhibitor effects, 569, 981, 1258
ascorbic acid metabolism, 257
autoregulation of renal blood flow, 1109
catecholamines effect, 906
 β -cell secretory responsiveness, 1042
 ω -3 fatty acid effects, 969
glucose conversion to lactate, 237
glyburide effects, 205
growth hormone effects, 428
heparan sulfate, 130
hepatocytes, vanadate effects on, 793
insulin prevention of receptor-effector coupling, 1611
ketoacidosis and prostacyclin production, 1585
mediobasal hypothalamus changes, 471
neonatal streptozocin, 610
neuropathy, 832, 959
neuropeptide Y concentrations, 321
parotid salivary gland function, 1381

peripheral neuropathy, 730
pregnancy and interrupted insulin, 764

proteolysis of skeletal muscle, 1117
renal aldose reductase activity, 1067
somatostatin accumulation, 752
thyrotropin secretion, 1301, 1351
urinary bladder dysfunction, 278
vanadyl treatment, 1390
vasopressin, 54

Streptozocin-induced insulitis
inhibition with lobenzarit, 558
islet protection, 379

Sucrose intake and kidney function, 679

Sulfonylureas
effect on insulin secretion, 422
glucose utilization of skeletal muscle, 1343
glyburide, glucose transport, 205

Suppression, 441

T

Teratogenesis, 1063, 1282
Thrombin, high-glucose effects, 212
Thymic hormones, 932
Thromboxane synthetase inhibitors, 1469
Thyrotrophs, 1301
Thyrotropin-releasing hormone, 1301, 1351

T-lymphocytes
abnormal and prediabetic screening, 1462
cyclosporin effects, 249
interleukin 2 production, 310
prevention of diabetes
cyclophosphamide-induced, 1492
injection of autoreactive, 1647

Tolbutamide, 416

TPA, β -cell secretory responsiveness, 1042

Transfusion, spleen cells, 24

Transplantation
human fetal pancreas, 448
islets of Langerhans, 244

cryopreservation, 386

Kidney, 516
rat islet tissue, 146

reciprocal allogeneic bone marrow, 894

Tricyclic antidepressants, 1161

Type I diabetes. *See* Insulin-dependent diabetes mellitus

Type II diabetes. *See* Non-insulin-dependent diabetes mellitus

Tyrosine hydroxylase activity, 959

U

Urinary
bladder function, 278, 1023
protein excretion, 1258

V

Vanadium
vanadate effects on hepatocytes, 793
vanadyl, long-term effects, 1390

Vasopressin
effects on hepatocytes, 793
secretion in rats, 54

Virus-induced diabetes, 316

Vitamin B₆, 881

W

WHO criteria for impaired glucose tolerance, 1630

Y

Yolk sac insulin, 39

Z

Zinc, 932

